Literature DB >> 9307059

Mapping of conformational B cell epitopes within alpha-helical coiled coil proteins.

J A Cooper1, W Hayman, C Reed, H Kagawa, M F Good, A Saul.   

Abstract

An approach to mapping antigenic B cell epitopes within alpha-helical coiled coil proteins has been developed and applied to two proteins: Streptococcal M protein and C. elegans paramyosin protein UNC-15. Overlapping peptides derived from an alpha-helical coiled coil conformational epitope were embedded between helical flanking peptides derived from the completely unrelated GCN4 leucine zipper peptide. The resulting chimeric peptides exhibited helical propensity. Chimeric peptides were tested for antigenicity (recognition by antibody) or immunogenicity (production of appropriate antibody response). A conformational epitope within the Streptococcal M protein recognised by three mAbs spanned 12 residues. Analysis of chimeric peptides based on C. elegans UNC-15 has enabled fine mapping of the minimal B cell epitope recognised by monoclonal antibody NE1-6B2 to seven non-contiguous residues (spanning 15 residues); the footprint of contact residues involved in antibody recognition being restricted to the hydrophilic face of the helix and covering five helical turns. This chimeric peptide epitope when coupled to diphtheria toxoid was highly immunogenic in mice and antisera recognised the conformationally dependent native peptide epitope. This approach has the potential to map conformational epitopes and design minimal epitopes for use as vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9307059     DOI: 10.1016/s0161-5890(97)00056-4

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

1.  Epitope mapping of the outer membrane protein P5-homologous fimbrin adhesin of nontypeable Haemophilus influenzae.

Authors:  L A Novotny; J A Jurcisek; M E Pichichero; L O Bakaletz
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  Recombinant HBHA boosting effect on BCG-induced immunity against Mycobacterium tuberculosis infection.

Authors:  G G Guerrero; C Locht
Journal:  Clin Dev Immunol       Date:  2011-05-23

Review 3.  Peptide-based synthetic vaccines.

Authors:  Mariusz Skwarczynski; Istvan Toth
Journal:  Chem Sci       Date:  2015-12-17       Impact factor: 9.825

Review 4.  Peptide-Based Vaccination for Antibody Responses Against HIV.

Authors:  Behazine Combadière; Manon Beaujean; Chloé Chaudesaigues; Vincent Vieillard
Journal:  Vaccines (Basel)       Date:  2019-09-02

Review 5.  Recent Advances in the Development of Peptide Vaccines and Their Delivery Systems Against Group A Streptococcus.

Authors:  Armira Azuar; Wanli Jin; Saori Mukaida; Waleed M Hussein; Istvan Toth; Mariusz Skwarczynski
Journal:  Vaccines (Basel)       Date:  2019-07-01

6.  Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2.

Authors:  Manisha Pandey; Victoria Ozberk; Sharareh Eskandari; Ahmed O Shalash; Michael A Joyce; Holly A Saffran; Christopher J Day; Ailin Lepletier; Belinda L Spillings; Jamie-Lee Mills; Ainslie Calcutt; Fan Fan; James T Williams; Danielle I Stanisic; Laetitia Hattingh; John Gerrard; Mariusz Skwarczynski; Johnson Mak; Michael P Jennings; Istvan Toth; D Lorne Tyrrell; Michael F Good
Journal:  Clin Transl Immunology       Date:  2021-03-07

7.  Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif.

Authors:  Viviane Villard; George W Agak; Géraldine Frank; Ali Jafarshad; Catherine Servis; Issa Nébié; Sodiomon B Sirima; Ingrid Felger; Myriam Arevalo-Herrera; Socrates Herrera; Frederic Heitz; Volker Bäcker; Pierre Druilhe; Andrey V Kajava; Giampietro Corradin
Journal:  PLoS One       Date:  2007-07-25       Impact factor: 3.240

8.  Identification of B-cell epitopes in an antigen for inducing specific class of antibodies.

Authors:  Sudheer Gupta; Hifzur Rahman Ansari; Ankur Gautam; Gajendra P S Raghava
Journal:  Biol Direct       Date:  2013-10-30       Impact factor: 4.540

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.